1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- Astellas Pharma Inc.
- F. Hoffmann-La Roche Ltd.
- Mylan NV
- Novartis AG
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Kidney Transplantation Therapeutics Market: About this market
The kidney transplantation therapeutics market analysis considers sales from selective cytokine inhibitors, immunosuppressive antimetabolites, and other drugs. Our analysis also considers the sales of kidney transplantation therapeutics in Asia, Europe, North America, and ROW. In 2018, the selective cytokine inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as superior immunosuppressive capabilities will play a significant role in the selective cytokine inhibitors segment to maintain its market position. Also, our global kidney transplantation therapeutics market report looks at factors such as the rising prevalence of CKD and renal impairments, availability of drugs in multiple dosage forms, and high dependency on immunosuppressants for kidney transplantations. However, side-effects of immunosuppressants, demand-supply imbalance, and stringent regulatory guidelines may hamper the growth of the kidney transplantation therapeutics industry over the forecast period.
Global Kidney Transplantation Therapeutics Market: Overview
High dependency on immunosuppressants for kidney transplantation
Significant advances in surgical techniques and ancillary healthcare techniques are increasing the demand for kidney transplantation. To overcome the challenge of transplant rejection, vendors have developed immunosuppressants. Thus, to reduce the risk and probability of the transplanted organ getting rejected, patients must undergo maintenance therapy using these immunosuppressants for the rest of their lives. This increase in the kidney transplantation and risks associated raises the demand for immunosuppressants leading to the expansion of the global kidney transplantation therapeutics market at a CAGR of over 4% during the forecast period.
Reimbursement policies for kidney transplantation
Patient assistance programs make drugs affordable for patients. These programs are associated with both government and non-government organizations. The Patient Protection and Affordable Care Act aims to improve the quality of health care by providing affordable health insurance. Similarly, the Medicare insurance coverage is expected to enable patients to take immunosuppressants on daily basisdaily to reduce the risk of transplant rejection for years after the transplantation as it is challenging to afford the costs associated with this therapy. Such initiatives are expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global kidney transplantation therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading kidney transplantation therapeutics manufacturers, that include Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Mylan NV, Novartis AG, Veloxis Pharmaceuticals A/S.
Also, the kidney transplantation therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The kidney transplantation therapeutics market analysis considers sales from selective cytokine inhibitors, immunosuppressive antimetabolites, and other drugs. Our analysis also considers the sales of kidney transplantation therapeutics in Asia, Europe, North America, and ROW. In 2018, the selective cytokine inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as superior immunosuppressive capabilities will play a significant role in the selective cytokine inhibitors segment to maintain its market position. Also, our global kidney transplantation therapeutics market report looks at factors such as the rising prevalence of CKD and renal impairments, availability of drugs in multiple dosage forms, and high dependency on immunosuppressants for kidney transplantations. However, side-effects of immunosuppressants, demand-supply imbalance, and stringent regulatory guidelines may hamper the growth of the kidney transplantation therapeutics industry over the forecast period.
Global Kidney Transplantation Therapeutics Market: Overview
High dependency on immunosuppressants for kidney transplantation
Significant advances in surgical techniques and ancillary healthcare techniques are increasing the demand for kidney transplantation. To overcome the challenge of transplant rejection, vendors have developed immunosuppressants. Thus, to reduce the risk and probability of the transplanted organ getting rejected, patients must undergo maintenance therapy using these immunosuppressants for the rest of their lives. This increase in the kidney transplantation and risks associated raises the demand for immunosuppressants leading to the expansion of the global kidney transplantation therapeutics market at a CAGR of over 4% during the forecast period.
Reimbursement policies for kidney transplantation
Patient assistance programs make drugs affordable for patients. These programs are associated with both government and non-government organizations. The Patient Protection and Affordable Care Act aims to improve the quality of health care by providing affordable health insurance. Similarly, the Medicare insurance coverage is expected to enable patients to take immunosuppressants on daily basisdaily to reduce the risk of transplant rejection for years after the transplantation as it is challenging to afford the costs associated with this therapy. Such initiatives are expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global kidney transplantation therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading kidney transplantation therapeutics manufacturers, that include Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Mylan NV, Novartis AG, Veloxis Pharmaceuticals A/S.
Also, the kidney transplantation therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Astellas Pharma Inc.
- F. Hoffmann-La Roche Ltd.
- Mylan NV
- Novartis AG
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits:
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Astellas Pharma Inc.
- F. Hoffmann-La Roche Ltd.
- Mylan NV
- Novartis AG
The following companies are recognised as the key players in the global kidney transplantation therapeutics market: Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Mylan NV, Novartis AG, Veloxis Pharmaceuticals A/S.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the reimbursement policies for kidney transplantation.”
According to the report, one of the major drivers for this market is the high dependency on immunosuppressants for kidney transplantation
Further, the report states that one of the major factors hindering the growth of this market is the side-effects of immunosuppressants.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the reimbursement policies for kidney transplantation.”
According to the report, one of the major drivers for this market is the high dependency on immunosuppressants for kidney transplantation
Further, the report states that one of the major factors hindering the growth of this market is the side-effects of immunosuppressants.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Astellas Pharma Inc.
- F. Hoffmann-La Roche Ltd.
- Mylan NV
- Novartis AG
- Veloxis Pharmaceuticals A/S.
Note: Product cover images may vary from those shown
